For instance, by combining CD28 and OX40 co-stimulatory domains, an earlier effector phenotype is merged with persistence and a long-lasting anti-tumor response, superior to that of CD28/4-1BB-incorporated CAR-T cells [73,74]. This evidence concerns the gene TNFRSF9 and neoplasm.